|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Market in India by 2020: A Healthy Decade
IKON Marketing Consultants, Sep 2011, Pages: 50
This report begins with the current scenario of Pharmaceutical market in India covering current market size and structure, market drivers, challenges and competitive landscape.
Chapter 2 highlights factors leading India's emergence as a major global player along with the global pharmaceuticals market overview.
The chapter 3 throws light on how the current decade going to remain healthy for the Indian pharmaceuticals Industry followed by Chapter 4 regulatory environment stating various laws and regulation effecting Indian pharmaceuticals Industry.
The report gives overall feel of how by 2020 the Indian pharma industry is going to grow healthy and going to make its existence noticeable in the Global Pharma Industry.
Market Highlights:
The Indian pharmaceutical market is highly regulated and fragmented, dominated by private Indian companies. Currently the domestic Indian Pharmaceutical market is valued at US$14.30 billion growing at a healthy double digit CAGR of 13% since 2005-06.
The major growth contributors are strong Indian demographics with robust economic YOY growth, increase in affordability of medicines, an increased percentage of disposable income being spent on healthcare and increased penetration of health insurance. The government has made public healthcare one of its top priorities by launching policies and programs aimed at making healthcare more affordable and accessible, especially in rural markets.
The global pharmaceuticals market is expected to grow at 7% to 8% CAGR over the next five years, reaching an anticipated US$ 1.7 trillion in 2020, India is going to rank among top 10 global player by 2015 itself. Looking at the immense potential Indian Pharmaceutical industry have, IKON estimates that the current decade will be going to change the prescription in Indian Pharmaceutical industry. India will emerge as a leading global player holding the rank among top 5 major global markets by 2020.
Who Should Buy This Report:
Pharma Companies, Investors and Venture Capitalists, Industry Analysts & Consultants, Corporate and Entrepreneurs, Industry association, Education and Government Institutes
|
|
|
|
